\-\ Texto\\:\\ \ \(0\)\
\-\ wbc\\-18\\.3\\,\\ multiple\\ viral\\ serologies\\ pending\ \(0\)\
\-\ csf\ \(2\)\
\-\ \\-\\-\\-\ \(165\)\
\-\ glucose\\-108\ \(1\)\
\-\ protein\\-21\\ \\(15\\-40\\)\ \(1\)\
\-\ wbc\\-0\ \(0\)\
\-\ rbc\\-0\ \(0\)\
\-\ no\\ organisms\ \(6\)\
\-\ no\\ growth\ \(12\)\
\-\ prominent\\ t2\\ hyperintense\\ areas\\ in\\ the\\ white\\ matter\\ with\\ focal\\ areas\\ of\\ enhancement\\ around\\ the\\ intrathecal\\ catheter\\ and\\ corpus\\ callosum\\.\ \(0\)\
\-\ methotrexate\\ induced\\ leukoencephalopathy\ \(1\)\
\-\ methotrexate\\ induced\\ leukoencephalopathy\ \(1\)\
\-\ viral\\ encephalopathy\ \(1\)\
\-\ adem\\ \\(acute\\ disseminated\\ encephalomyelitis\\)\ \(0\)\
\-\ pml\ \(0\)\
\-\ binswanger\\ disease\ \(0\)\
\-\ radiation\\ necrosis\ \(3\)\
\-\ patient\\ with\\ stage\\ iv\\ non\\-hodgkins\\ lymphoma\\ with\\ right\\ triceps\\ muscle\\ and\\ bilateral\\ lower\\ extremity\\ weakness\\ along\\ with\\ bilateral\\ hand\\ paresthesias\\.\\ \\ also\\ noted\\ to\\ have\\ a\\ recent\\ \\"decline\\ in\\ mental\\ status\\"\\ all\\ following\\ intrathecal\\ administration\\ of\\ methotrexate\\.\ \(0\)\
\-\ the\\ temporal\\ relationship\\ between\\ the\\ methotrexate\\ administration\\ and\\ onset\\ of\\ symptoms\\ with\\ mr\\ changes\\ and\\ normal\\ csf\\ fluid\\ analysis\\ suggests\\ that\\ methotrexate\\ is\\ the\\ culprit\\.\\ \\ however\\,\\ the\\ patient\\ does\\ have\\ a\\ white\\ count\\ and\\ viral\\ serologies\\ are\\ pending\\.\\ \\ the\\ areas\\ of\\ enhancement\\ are\\ likely\\ part\\ of\\ the\\ same\\ process\\ given\\ the\\ pericatheter\\ location\\ of\\ most\\ of\\ the\\ foci\\.\\ \\ some\\ of\\ the\\ foci\\,\\ however\\,\\ may\\ be\\ new\\ foci\\ of\\ nhl\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ methotrexate\\:\\ 0\\.44494956878995473\ \(0\)\
\-\ serologies\\:\\ 0\\.24186877442195331\ \(0\)\
\-\ viral\\:\\ 0\\.2189953057791941\ \(0\)\
\-\ intrathecal\\:\\ 0\\.20581806696210744\ \(0\)\
\-\ foci\\:\\ 0\\.1940477104148047\ \(0\)\
\-\ leukoencephalopathy\\:\\ 0\\.19065332801535323\ \(0\)\
\-\ the\\:\\ 0\\.17370076145392394\ \(0\)\
\-\ areas\\:\\ 0\\.16118845528981965\ \(0\)\
\-\ induced\\:\\ 0\\.15695661247196288\ \(0\)\
\-\ of\\:\\ 0\\.13938331101999002\ \(0\)\
\-\ pending\\:\\ 0\\.13017888238289926\ \(0\)\
\-\ binswanger\\:\\ 0\\.12655952976118368\ \(0\)\
\-\ administration\\:\\ 0\\.1260436492342715\ \(0\)\
\-\ csf\\:\\ 0\\.12506507769026445\ \(0\)\
\-\ pericatheter\\:\\ 0\\.12093438721097666\ \(0\)\
\-\ culprit\\:\\ 0\\.1113181425059362\ \(0\)\
\-\ pml\\:\\ 0\\.10917956256181847\ \(0\)\
\-\ nhl\\:\\ 0\\.10917956256181847\ \(0\)\
\-\ white\\:\\ 0\\.10442654813222094\ \(0\)\
\-\ however\\:\\ 0\\.09368135983936475\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.09267609575836848\ \(0\)\
\-\ decline\\:\\ 0\\.0920856530958553\ \(0\)\
\-\ enhancement\\:\\ 0\\.09110137058391278\ \(0\)\
\-\ paresthesias\\:\\ 0\\.09097519591528805\ \(0\)\
\-\ disseminated\\:\\ 0\\.08571041930263616\ \(0\)\
\-\ organisms\\:\\ 0\\.085350053365081\ \(0\)\
\-\ bilateral\\:\\ 0\\.08506379267490644\ \(0\)\
\-\ adem\\:\\ 0\\.08499881160315755\ \(0\)\
\-\ relationship\\:\\ 0\\.08399548475067248\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.0833647712077839\ \(0\)\
\-\ and\\:\\ 0\\.08176490715473278\ \(0\)\
\-\ triceps\\:\\ 0\\.0813589512102476\ \(0\)\
\-\ have\\:\\ 0\\.07906794313222348\ \(0\)\
\-\ with\\:\\ 0\\.07748144028617292\ \(0\)\
\-\ callosum\\:\\ 0\\.07454150281405572\ \(0\)\
\-\ analysis\\:\\ 0\\.0735952287159228\ \(0\)\
\-\ suggests\\:\\ 0\\.07299843525973136\ \(0\)\
\-\ corpus\\:\\ 0\\.07214878355017268\ \(0\)\
\-\ part\\:\\ 0\\.07071458374165666\ \(0\)\
\-\ catheter\\:\\ 0\\.07034786701042323\ \(0\)\
\-\ mental\\:\\ 0\\.06897087235185403\ \(0\)\
\-\ count\\:\\ 0\\.06533941747786098\ \(0\)\
\-\ growth\\:\\ 0\\.06525559058506976\ \(0\)\
\-\ around\\:\\ 0\\.06316484968334786\ \(0\)\
\-\ stage\\:\\ 0\\.06302182461713575\ \(0\)\
\-\ hyperintense\\:\\ 0\\.06295086124733189\ \(0\)\
\-\ same\\:\\ 0\\.06260138915293399\ \(0\)\
\-\ prominent\\:\\ 0\\.0623280146218914\ \(0\)\
\-\ hand\\:\\ 0\\.06186220031405701\ \(0\)\
\-\ temporal\\:\\ 0\\.060792072547203875\ \(0\)\
\-\ necrosis\\:\\ 0\\.06049242140479307\ \(0\)\
\-\ matter\\:\\ 0\\.06025727495255485\ \(0\)\
\-\ are\\:\\ 0\\.06005884706271526\ \(0\)\
\-\ process\\:\\ 0\\.059354627646813575\ \(0\)\
\-\ weakness\\:\\ 0\\.057757048004483884\ \(0\)\
\-\ extremity\\:\\ 0\\.0569992728462668\ \(0\)\
\-\ iv\\:\\ 0\\.05654585639430202\ \(0\)\
\-\ muscle\\:\\ 0\\.05619349945947109\ \(0\)\
\-\ status\\:\\ 0\\.0552276447921412\ \(0\)\
\-\ location\\:\\ 0\\.055106479755175734\ \(0\)\
\-\ new\\:\\ 0\\.0547492074308674\ \(0\)\
\-\ does\\:\\ 0\\.05471007254300424\ \(0\)\
\-\ given\\:\\ 0\\.05443917646090043\ \(0\)\
\-\ recent\\:\\ 0\\.05358459282870279\ \(0\)\
\-\ along\\:\\ 0\\.0530196981607696\ \(0\)\
\-\ radiation\\:\\ 0\\.052443678317465756\ \(0\)\
\-\ patient\\:\\ 0\\.05147949723522355\ \(0\)\
\-\ no\\:\\ 0\\.05146981424189692\ \(0\)\
\-\ between\\:\\ 0\\.05142029775479821\ \(0\)\
\-\ mr\\:\\ 0\\.051206152025926197\ \(0\)\
\-\ onset\\:\\ 0\\.05081701537961665\ \(0\)\
\-\ some\\:\\ 0\\.04979311006815761\ \(0\)\
\-\ changes\\:\\ 0\\.04782794873896748\ \(0\)\
\-\ following\\:\\ 0\\.04747551720743238\ \(0\)\
\-\ focal\\:\\ 0\\.04733701380866877\ \(0\)\
\-\ likely\\:\\ 0\\.04729115158988475\ \(0\)\
\-\ lymphoma\\:\\ 0\\.047131817336723704\ \(0\)\
\-\ all\\:\\ 0\\.04710920395185072\ \(0\)\
\-\ fluid\\:\\ 0\\.04569276869893437\ \(0\)\
\-\ t2\\:\\ 0\\.04553050593051069\ \(0\)\
\-\ symptoms\\:\\ 0\\.04330004943505133\ \(0\)\
\-\ acute\\:\\ 0\\.042810848662992965\ \(0\)\
\-\ noted\\:\\ 0\\.04195906369645439\ \(0\)\
\-\ most\\:\\ 0\\.041186019680578376\ \(0\)\
\-\ lower\\:\\ 0\\.04043980875771798\ \(0\)\
\-\ may\\:\\ 0\\.039824938177980294\ \(0\)\
\-\ in\\:\\ 0\\.03937413100745683\ \(0\)\
\-\ multiple\\:\\ 0\\.038708313711893406\ \(0\)\
\-\ also\\:\\ 0\\.03722443521464192\ \(0\)\
\-\ that\\:\\ 0\\.034343097700325814\ \(0\)\
\-\ disease\\:\\ 0\\.03321948882300659\ \(0\)\
\-\ normal\\:\\ 0\\.0323116779939436\ \(0\)\
\-\ be\\:\\ 0\\.032103285018174374\ \(0\)\
\-\ right\\:\\ 0\\.026237653951462478\ \(0\)\
\-\ is\\:\\ 0\\.021672588452280435\ \(0\)\
\-\ to\\:\\ 0\\.019784444498575412\ \(0\)\
